CoChat
Sign Up
Cited by 173Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal Infections and Studies

New and emerging treatments for fungal infections

Open access
Pasqualotto, A. C., Denning, D. W.·2008·Journal of Antimicrobial Chemotherapy
DOI 10.1093/jac/dkm428
Open this paper in CoChat — free accountOpen PDF

Abstract

Although several new antifungal drugs have been licensed in the last 5 years, some patients remain difficult to treat. The main reasons for this include intrinsic or acquired antifungal resistance, organ dysfunction preventing the use of some agents and drug interactions. In addition, some drugs penetrate poorly into sanctuary sites including eye and urine, and others are associated with considerable adverse events. Here, we review the preclinical and clinical development progress with four new antifungal agents: isavuconazole, ravuconazole, albaconazole and aminocandin. Isavuconazole and ravuconazole are extremely similar, with a broad spectrum of activity, a very long half-life and large volume of distribution and good in vivo data supporting their efficacy in invasive aspergillosis and candidosis. Both compounds are in early Phase 3 development. Albaconazole has also shown very potent activity against species of Candida, Cryptococcus and Aspergillus. It was well tolerated and effective in women with vaginal candidosis. Aminocandin is an intravenous-only echinocandin with in vivo activity against Candida spp. and Aspergillus spp. Its extended half-life probably permits dosing less frequently than once a day. Overall these new antifungal agents in development offer extended half-lives, possibly reduced drug interaction profiles and good tolerance. Their antifungal spectrum is narrower than posaconazole and probably similar to voriconazole (isavuconazole and ravuconazole) and caspofungin (aminocandin). Licensure and determination of their place in clinical practice requires randomized clinical studies, which are or will be underway.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkm428

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 58 · Cited by 173

Research works printed but not linked: 24

  1. Breuker I, Meis JF, Verweij PE et al. In vitro activity of the new azole BAL4815 against Candida isolates comprising resistant C. albicans and less susceptible Candida spp. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract M-1621. American Society for Microbiology, Washington, DC, USA.
  2. Seifert H, Aurbach U, Stefanik D et al. In vitro activity of isavuco- nazole and other antifungal agents against Candida bloodstream iso- lates. Antimicrob Agents Chemother 2007; 51: 1818-21.
  3. Ghannoum M, Isham N. Antifungal activity of BAL4815, a novel azole against dermatophytes and emerging non-dermatophyte fungi including Zygomycetes. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract M-1623. American Society for Microbiology, Washington, DC, USA.
  4. Warn PA, Mosquera J, Sharp A et al. In vivo efficacy of the tria- zole BAL8557 (BAL) compared to voriconazole (VOR), itraconazole (ITC) and caspofungin (CAS) by a new qPCR and quantitative culture in neutropenic murine model of Aspergillus flavus. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract B-48. American Society for Microbiology, Washington, DC, USA.
  5. Warn PA, Sharp A, Denning DW. Dose response curves and dose fractionation studies with BAL8557 in a murine model of dissemi- nated candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract B-47. American Society for Microbiology, Washington, DC, USA.
  6. Te Dorsthorst D, Verweij PE, Meis JF et al. Pharmacodynamics of BAL4815: a new azole antifungal in a mouse model of systemic infection. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004.
  7. Mouton JW, Schmitt-Hoffmann A, Punt N. Monte Carlo simu- lations of BAL8557: a new watersoluble azole with antifungal activity. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract A-134. American Society for Microbiology, Washington, DC, USA.
  8. Viljoen JJ, Mitha I, Heep M et al. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind, randomized, multicenter trial for the treatment of esopha- geal candidiasis in immunocompromised adults. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract LB2-32. American Society for Microbiology, Washington, DC, USA.
  9. Marino MR, Mummanei V, Norton J et al. Ravuconazole exposure-response relationship in HIV-patients with oropharyngeal candidiasis. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001.
  10. Nweze E, Curfs-Breuker I, Janssen B et al. In vitro activity of posaconazole with seven antifungal agents against 80 clinical and 15 environmental isolates of Exophiala dermatidis. In: Abstracts of the Forty-sixth Interscience Conference on Antimicriobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract M-1588. American Society for Microbiology, Washington, DC, USA.
  11. Wheat L, Connolly P, Smedema M et al. Activity of newer tria- zoles against fluconazole-resistant Histoplasma capsulatum isolates. In: Focus on Fungal Infections Sixteenth Annual Conference, Las Vegas, USA, 2006. Poster no. P-054.
  12. Petraitiene R, Petraitis V, Sarafandi A et al. Synergistic activity between ravuconazole and the echinocandin micafungin in treatment of experimental pulmonary aspergillosis. In: Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract M-857. American Society for Microbiology, Washington, DC, USA.
  13. Olsen SJ, Mummaneni V, Rolan P et al. Ravuconazole single ascending oral dose study in healthy subjects. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract A-838. American Society for Microbiology, Washington, DC, USA.
  14. Grasela DM, Olsen SJ, Mummaneni V et al. Ravuconazole: mul- tiple ascending oral dose study in healthy subjects. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract A-839. American Society for Microbiology, Washington, DC, USA.
  15. Bello A, Russo R, Grasela D et al. Pharmacokinetics of intrave- nous BMS-379224 ( pro-drug of ravuconazole) in healthy male sub- jects. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003.
  16. Mummaneni V, Geraldes M, Hadjilambris OW et al. Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract A-841. American Society for Microbiology, Washington, DC.
  17. Beale M, Queiroz-Telles F, Banhegyi D et al. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001. J-1621. American Society for Microbiology, Washington, DC, USA.
  18. Lin P, Mickiene D, Roden MM et al. Pharmacokinetics and safety of ravuconazole for prophylaxis in patients undergoing allo- geneic hematopoietic stem cell transplantation. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-220. American Society for Microbiology, Washington, DC, USA.
  19. Bartroli X, Uriach J. A clinical multicenter study comparing effi- cacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicriobial Agents and Chemotherapy, Washington, DC, 2005.
  20. Moore CB, Denning DW. In vitro activity of HMR3270 against Candida spp. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 2001. Abstract F-2147. American Society for Microbiology, Washington, DC, USA.
  21. Dromer F, Abdoul L, Improvisi L et al. In vitro activity of HMR 3270 against yeasts and filamentous fungi. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract F-2148. American Society for Microbiology, Washington, DC, USA.
  22. Warn P, Sharp A, Denning DW. The in vivo activity of HMR3270 in temporarily neutropenic murine models of disseminated infection caused by Aspergillus fumigatus (2 strains). In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract J-1618. American Society for Microbiology, Washington, DC, USA.
  23. Najvar LK, Bocanegra R, Olivo M et al. Once is enough: single dose aminocandin (AC) therapy of candidemia. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract F-496. American Society for Microbiology, Washington, DC, USA.
  24. Lowther J, Schio L, Platel D et al. In vivo efficacy of HMR3270, a new candin antifungal agent, in a mouse model of candidiasis. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents amd Chemotherapy, Chicago, IL, 2001. Abstract F-2149. American Society for Microbiology, Washington, DC, USA.

Authors
Pasqualotto, A. C., & Denning, D. W.
Affiliations
University of Manchester (GB)
Corresponding author
Pasqualotto, A. C.
ORCID
Venue
Journal of Antimicrobial Chemotherapy
Publisher
Oxford University Press (OUP)
Published
2008-01-01
Volume
61
Issue
Supplement 1
Pages
i19-i30
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
DOI
10.1093/jac/dkm428
OpenAlex
W2103578848
Cited by
173
References
58
Citations by year
2025: 3 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 4 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 9 · 2014: 12 · 2013: 11 · 2012: 6
FWCI
2.56
Type
journal article
Language
en
Open access
Locations
  • Journal of Antimicrobial Chemotherapy (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
Funders
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
antifungal agents, isavuconazole, ravuconazole, invasive aspergillosis, candidiasis, Cryptococcus, antifungal resistance, drug interactions, adverse events, echinocandins
MeSH terms
Animals, Antifungal Agents, Humans, Mycoses, Quinazolines, Stereoisomerism, Triazoles, Drug Resistance, Fungal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review